An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02305563 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
70
Enrollment
INDUSTRY
Sponsor class

Stopped Business objectives have changed, slow accrual, the standard of care for the patient population changed and we were unable to accrue any longer.

Conditions

Interventions

Sponsor

Bristol-Myers Squibb